(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USO DE UM ANTICORPO ANTI-CD19 PARA TRATAR MIASTENIA GRAVIS

Em AnáliseInvention PatentPCT · US2022028063

Application data

Number

112023022133

Type

Invention Patent

Filing

05/06/2022

Publication

12/26/2023

PCT

US2022028063

Progress at the INPI

  1. Filing05/06/22
  2. Publication
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The application was filed at the INPI on 05/06/2022. It awaits formal examination and publication in the RPI gazette.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 02/03/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

VIELA BIO, INC.

US

See this company's full portfolio

Inventors

E. K. (pessoa física)

US

J. R. (pessoa física)

US

L. A. (pessoa física)

US

Technical data

IPC Classification

Priority claims

US

63/185,613 · 05/07/2021

US

63/303,655 · 01/27/2022

Abstract

USO DE UM ANTICORPO ANTI-CD19 PARA TRATAR MIASTENIA GRAVIS. Métodos para usar um anticorpo anti-CD19 para tratar doença autoimune são divulgados neste documento. Em particular, a divulgação fornece o uso de Inebilizumabe, um anticorpo monoclonal IgG1 kappa humanizado, otimizado por afinidade e afucosilado para tratar a miastenia gravis.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Alteração de sede deferida

#25.7

02/03/2026

RPI 2874

Notificação de entrada na fase nacional - PCT

#1.3

12/26/2023

RPI 2764

Alteração de dados cadastrais

#1.1

10/31/2023

RPI 2756

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.